[Fulvestrant for the treatment of locally advanced ormetastatic breast cancer]
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Gonzalez L
Record ID 32014000260
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage policy related issues regarding the use of fulvestrant in patients with locally advanced or metastatic breast cancer.
Authors' recomendations: The evidence found is of good methodological quality. It supports the use of fulvestrant as second line hormonal therapy; the 500 mg dose being most widely recommended. When assessing the use of fulvestrant in combination with anastrozole as first line therapy, the results of the RCT found are contradictory; therefore new results are required to enable recommending this regimen.
Project Status: Completed
Year Published: 2013
URL for published report: https://www.iecs.org.ar/home-ets/?cod_publicacion=1543&origen_publicacion=publicaciones
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Neoplasm Metastasis
- Estrogen Antagonists
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.